Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | MERTK | Q12866 | 1/20 | 0.50 |
| ▸ | WNT1 | P04628 | 4/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834177 | 1.00 | ATR (0.57) | ATRDYRK1AROCK2AXLMERTK | |
| SCHEMBL27201475 | 0.82 | DYRK1A (0.71) | DYRK1AWNT1 | |
| SCHEMBL27201480 | 0.81 | L3MBTL1 (0.56) | ATRMAP4K4 | |
| SCHEMBL30885229 | 0.81 | L3MBTL1 (0.56) | ATRMAP4K4 | |
| SCHEMBL27201398 | 0.80 | MAP4K4 (0.50) | ROCK2KMT2AMAP4K4 | |
| SCHEMBL30885217 | 0.80 | MAP4K4 (0.50) | ROCK2KMT2AMAP4K4 | |
| SCHEMBL14980322 | 0.78 | DRD2 (0.63) | ATRDYRK1AROCK2AXLMERTK | |
| SCHEMBL18611763 | 0.77 | AXL (0.66) | ATRDYRK1AROCK2AXLMERTK | |
| SCHEMBL27201638 | 0.77 | MAP4K4 (0.50) | ATRAXLMAP4K4 | |
| SCHEMBL24149990 | 0.77 | ATR (0.45) | ATRDYRK1AROCK2WNT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | ATR 1089/4885DYRK1A 2404/4885ROCK2 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.